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Abstract. – OBJECTIVE: Gut barrier is a
functional unit organized as a multi-layer sys-
tem and its multiple functions are crucial for
maintaining gut homeostasis. Numerous scien-
tific evidences showed a significant associa-
tion between gut barrier leaking and gastro-in-
testinal/extra-intestinal diseases.
MATERIALS AND METHODS: In this review
we focus on the relationship between gut barri-
er leaking and human health. At the same time
we speculate on the possible new role of gut
barrier protectors in enhancing and restoring
gut barrier physiology with the final goal of pro-
moting gut health.
RESULTS: The alteration of the equilibrium in
gut barrier leads to the passage of the luminal
contents to the underlying tissues and thus into
the bloodstream, resulting in the activation of
the immune response and in the induction of gut
inflammation. This permeability alteration is the
basis for the pathogenesis of many diseases, in-
cluding infectious enterocolitis, inflammatory
bowel diseases, irritable bowel syndrome, small
intestinal bacterial overgrowth, celiac disease,
hepatic fibrosis, food intolerances and also
atopic manifestations. Many drugs or com-
pounds used in the treatment of gastrointestinal
disease are able to alter the permeability of the
intestinal barrier. Recent data highlighted and in-
troduced the possibility of using gelatin tannate,
a mucosal barrier protector, for an innovative ap-
proach in the management of intestinal dis-
eases, allowing an original therapeutic orienta-
tion with the aim of enhancing mucus barrier ac-
tivity and restoring gut barrier.
CONCLUSIONS: These results suggest how
the mucus layer recovering, beside the gut mi-
crobiota modulation, exerted by gut barrier pro-
tectors could be a useful weapon to re-estab-
lish the physiological intestinal homeostasis af-
ter an acute and chronic injury.
Key words:
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Introduction
The gastrointestinal tract is the most exposed hu-
man habitat to the external environment with a sur-
face area of 200 m2. Every day, thousands of micro-
organisms and compounds derived from the diges-
tion are in contact with it. In this condition, the role
of the gut barrier is crucial. Indeed, it provides a
complex defense system capable of separating the
intestinal contents from the host tissues, modulating
the absorption of nutrients and allowing the interac-
tion between the resident microbial flora and the
mucosal immune system, inhibiting the transloca-
tion of pathogens in underlying tissues1.
In particular, the gut barrier is a functional unit
organized as a multi-layer system. It is divided in
two main parts: a physical barrier, which prevents
bacterial adhesion and regulates paracellular diffu-
sion, and a functional deeper barrier that is able to
discriminate between pathogens and commensal
microorganisms, by organizing an immunological
tolerance towards commensals and an immune re-
sponse towards pathogens. In addition, there are
other mechanisms involved in maintaining the gut
luminal homeostasis. For example, the low pH of
gastric juice is bactericidal and therefore acts
against infectious agents, while pancreatic en-
zymes are able to damage the bacterial cell.
The gut barrier starts from the resident micro-
biota. It competes with pathogens to gain space
and energy resources, processes the molecules re-
quired for mucosal integrity and modulates the in-
testinal immunological response. The next level is
represented by the mucus layer. It separates the lu-
minal content from the deepest layers and contains
antimicrobial products, and secretory IgA. Below
the mucus, there is the monolayer of intestinal ep-
ithelial cells. This is able to form a physical barrier
and contains the immunological cells. These cells
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million genes and have a mutualistic relationship
with their host. Gut microbiota plays several
functions: barrier, synthesis, immune stimulation,
metabolism of nutrients, and metabolism of drugs
and toxins. In particular, the microbiota is crucial
for the digestion of energy substrates, the produc-
tion of vitamins and hormones, and the protection
of the host from the pathogenic species2,7,8. In
fact, the microbiota is able to consume the nutri-
ents necessary for survival of pathogens and can
produce molecules, which inhibit the growth of
pathogenic flora. Several studies showed that
Lactobacilli and Bifidobacteria produce bacterici-
dal acidic substances, such as lactic acid, bacteri-
ocins and short chain fatty acids (SCFA). In ani-
mal models these products can suppress the
growth of Salmonella Typhimurium. Recently, it
has been shown that a compound formed by Bac-
teroides thetaiotamicron and Eubacterium rectale
can induce the host production of mucosal gly-
cans. These are exclusively used by these two
bacterial strains and not by pathogens, which
therefore are not able to proliferate9-11.
Moreover, the enteric microflora produces nu-
trients for the mucosal cells. Bacteroides thetaio-
tamicron colonizes the outer mucus layer and can
degrade peptides and glycans that constitute the
mucus, producing SCFA, such as butyrate. The
SCFA are involved in the stimulation of mucus
production, in blocking the invasion and adhe-
sion of Escherichia coli, and in increasing mu-
cosal total and pathogen-specific IgA12-14.
The microflora alteration is the basis of many
gastrointestinal disorders such as gastritis, peptic
ulcer, IBS, IBD and even gastric and colon cancer.
In IBD, for example, the concentration of bacteria
adhering to the intestinal enterocytes is higher
compared to healthy controls and increases pro-
gressively with the severity of the pathology. In
addition, there is a reduction in bacterial diversity
with an increase in Enterobacteriaceae, including
E. coli, and a marked reduction in Bacteroides and
Clostridium. This condition leads to the reduction
of enterocytes growth and maturation with a con-
sequent increase in intestinal permeability15-18.
Intestinal mucus
The mucus is the first physical barrier that bac-
teria encounter within the digestive tract. It acts as
a shield for the epithelium, protecting it from
harmful microorganisms and antigens, but also as
a lubricant for intestinal motility. It consists of
two layers: an inner layer, firmly adherent to the
epithelial cells and approximately 50 µm thick,
can present pathogenic antigens to the cells of the
functional barrier with the aim of developing an
appropriate immune response1-3.
The deep part of the gut barrier is represented
by a complex network of immune cells, which are
organized in a specialized and compartmentalized
structure known as “gut associated lymphoid tis-
sue” or GALT. The GALT consists of lymphoid
follicles and is one of the major lymphoid organs,
containing up to 70% of the body immune cells.
It is responsible for the response to pathogenic
microorganisms and the immune tolerance to
commensal bacteria. This ability is explicated
through a physiological relationships with the sur-
face layer and the intimate contact with the exter-
nal environment through specific immune cells:
the dendritic cells and the M-cells within the Pey-
er's patches. These cells have the ability to ac-
quire microorganisms and macromolecules and to
present antigens to T lymphocytes, which pro-
duce cytokines activating the immune response.
The integrity of these structures is required for
the maintenance of the normal intestinal perme-
ability. The alteration of this equilibrium leads to
the passage of the luminal contents to the underly-
ing tissues and thus into the bloodstream (gut bar-
rier leaking), resulting in the activation of the im-
mune response and in the induction of gut inflam-
mation. This permeability alteration is the basis
for the pathogenesis of many diseases, including
not only infectious enterocolitis and inflammatory
bowel diseases (IBD), but also irritable bowel syn-
drome4, small intestinal bacterial overgrowth (SI-
BO), celiac disease, hepatic fibrosis, food intoler-
ances and also atopic manifestations1,5,6.
The assessment of the intestinal permeability
and of the related molecular mechanisms may
become an interesting parameter to consider in
clinical practice for studying and, especially,
treating these diseases. In vitro models (Caco2
and HT29-MTX cells) and in vivo non-invasive
techniques (sugar tests and tests with radioiso-
topes) are effective methods for this type of eval-
uation. Finally, the modulation of the various
barrier components is crucial for the control of
intestinal permeability1.
The gut barrier
Gut microbiota
The gut, which under physiological conditions
also includes fungi and bacteriophages, harbors
about 1 kg of bacteria that contain more than 3
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and an outer layer, looser and less adherent,
which is approximately 100 µm thick, according
to the measurements made in animal models19.
The inner mucosal layer is dense and does not
allow bacteria to penetrate, thus making the ep-
ithelial cell surface free from bacteria. The inner
layer turns into the outer layer, which is the habi-
tat of commensal flora. Both layers are organized
around the highly glycosylated mucin MUC2,
which forms an amorphous polymer-like cover
and is secreted by goblet cells. The MUC2 mucin
is a molecule that has been preserved along the
evolution since the first metazoans20.
After secretion, the MUC2 mucin is organized
in a hydrated and expanded network and forms,
together with other secreted proteins, a well-or-
ganized mucus layer21. The protein composition
is similar in the two mucosal layers since it is de-
rived from a common cellular source. The physi-
ological microbial flora resides in the outer mu-
cus layer, while the inner layer is impervious to
bacteria and acts as a protective barrier for the
epithelial cell surface. This compartmentalization
is essential for intestinal homeostasis within a
highly colonized colon22,23.
The importance of the mucosal barrier was
further demonstrated in MUC2 deficient animals.
In this model, the bacteria are in direct contact
with the epithelial cells, but also with intestinal
crypts. The increase in intestinal permeability,
caused by the loss of mucus barrier, triggers an
inflammatory reaction and, subsequently, can
promote the development of colon cancer. Fur-
thermore, mucus exerts not only a barrier func-
tion. Its content in glycans, linked to mucin
MUC2, serves as nutrient for bacteria, but also as
a binding site and, induces the selection of spe-
cific microbial species, which are essential for
maintaining the integrity, homeostasis and in-
testinal function24-26.
Epithelial cells
The intestinal epithelium is organized in a
monolayer of cells, with a thickness of only 20
µm and composed by 5 different cell types: ente-
rocytes, endocrine cells, M cells, G cells and
Paneth cells. The enterocytes are the most repre-
sented cell type. They act as a physical barrier
that inhibits the translocation of luminal contents
in the inner tissues. They are connected by inter-
cellular structures called tight junctions calls.
These are characterized by trans-membrane pro-
teins, which interact with adjacent cells and with
intracellular proteins associated with the cy-
toskeleton27. Together, these components form a
complex and homogeneous network. In the in-
testinal epithelium there are two main types of
junctions: the adherens junctions (AJs) and the
tight junctions (TJs). Both types are formed by
in different concentrations of cadherin, claudin,
and zonuline.
The modulation of these junctions, and there-
fore of the epithelial barrier permeability, takes
place through the myosin phosphorylation and
the actin-myosin complex contraction. An alter-
ation of this balance increases the mucosal per-
meability, causing the passage of endoluminal
molecules in the deeper layers, determining the
activation of the adaptive immune response and
leading to the inflammatory state28-31. This condi-
tion is observed especially during the infectious
enterocolitis and IBD. In the first condition, the
Entero- hemorrhagic E. coli (EHEC), and En-
tero-pathogenic E. coli (EPEC) have the ability
to adhere to intestinal epithelial cells and to
break the integrity of the barrier through the al-
teration of tight junctions. Moreover, a dysfunc-
tion of the AJ protein has been described in IBD.
This is due to a reduction of E-cadherin. This al-
teration leads to the weakening of intercellular
adhesion and to an inflammatory response. Re-
cent studies showed that high concentrations of
IFN-γ and TNF-α, typical found in UC and CD,
can cause a reorganization of numerous proteins
that constitute the tight junctions, such as
zonulin-1, JAM-A, occludin, claudin-1 and
claudin-4. Even in this case, this leads to an in-
creased intestinal permeability, which is also
found in IBS, especially in the subgroup of IBS
with diarrhea (IBS-D)32,33.
Gut barrier leaking
and related diseases
The ability of the various intestinal barrier
components to ensure the physiological perme-
ability even in presence of pathogenic factors is
essential for health maintenance. In fact, when
the protection exerted by the intestinal barrier
fails, the immune cells come in direct contact
with antigens in the intestinal lumen. This results
in the impairment of normal physiological barrier
functions, such as the immune response to
pathogens (bacteria, viruses, fungi and parasites),
the recognition of “self” antigens, the tolerance
towards the commensal flora and the desensitiza-
tion to food antigens. Numerous scientific evi-
dences showed a significant association between
gastro-intestinal and extra-intestinal diseases and
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permeability alteration. Among these, autoim-
mune diseases, including celiac disease, IBD, di-
abetes mellitus type I, multiple sclerosis and
rheumatoid arthritis, but also liver cirrhosis,
acute pancreatitis, infectious gastroenteritis, and
small intestinal bacterial growth (SIBO) are in-
cluded. Even diseases not directly related to the
mucosal barrier function, such as heart failure or
autism, can cause an increase in intestinal perme-
ability. In some cases, such as in IBD and celiac
disease, the permeability alteration could be the
primary pathogenic cause. In others, such as in
liver cirrhosis, it would lead to the translocation
of microbial antigens into the entero-hepatic cir-
culation with the consequent exacerbation of liv-
er fibrosis and of portal hypertension, and a fur-
ther increase in permeability1.
Whether the alteration of the barrier function
is an epiphenomenon, an early event, or an essen-
tial step in the pathogenesis of these diseases,
needs to be clarified. However, it is well known
that an increase in intestinal permeability con-
tributes to the exacerbation of these pathologies.
In many cases, the same drugs that lead to dis-
ease resolution, even temporarily, also lead to a
recovery of the permeability and therefore to an
adequate physiological intestinal homeostasis24.
IBD are an example of increased intestinal
permeability. It plays a central role in the patho-
genesis of this disease. In this case, the altered
intestinal permeability precedes the development
of the disease. The exact pathogenesis remains
unknown, but it certainly involves genetic, im-
munological and environmental factors that initi-
ate the autoimmune process. In Crohn's disease
clinically asymptomatic patients, an increase in
intestinal epithelial permeability anticipates of
about 1 year the recurrence of the disease. This
suggests that a defect in intestinal permeability is
an early event and is predictive for the clinical
exacerbation of the disease34. While the primary
defect of the intestinal barrier seems to be in-
volved in the early stages of IBD pathogenesis,
the production of cytokines, including IFN-γ and
TNF-α, secondary to the inflammatory process,
would serve to perpetuate the increase in intesti-
nal permeability following the reorganization of
the proteins that constitute the intercellular junc-
tions. In this manner a vicious cycle is created.
The primary dysfunction of the barrier would
cause an initial passage of luminal contents,
which in turn triggers an immune response with
the maintenance of an altered permeability and
the exacerbation of the disease35.
Therefore, in this context new therapeutic
strategies focused on the recovery of the physio-
logical function of the intestinal barrier may offer
an innovative approach for the clinical improve-
ment of these highly debilitating chronic dis-
eases.
The pharmacological modulation
of the intestinal barrier
Despite clear evidence, the measurement of in-
testinal permeability is still far from becoming a
laboratoristic parameter able to drive the clinical
practice. However, many drugs or compounds
used in the treatment of gastrointestinal disease
are able to alter the permeability of the intestinal
barrier. The main substances used in gastroen-
terology clinical practice are steroids, aminosali-
cylates, biologics (i.e., anti-TNF-α), probiotics
and mucosal protectors. While corticosteroids,
salicylates and anti-TNF-α act in the modulation
of intestinal permeability by reducing intestinal
inflammation, probiotics appear to act through
the modulation of mucin production and of ep-
ithelial junctions strength. Finally, emerging evi-
dences suggest an important role for the mucosal
protectors, such as the gelatin tannate, a medical
device recently introduced also in Italy for the
treatment of acute diarrhea.
Corticosteroids are the mainstay therapy for
the induction of clinical remission in mild to se-
vere Crohn's disease. Among these, prednisone is
able to reduce intestinal permeability in 50% of
patients, measured through the analysis of the re-
lationship lactulose/mannitol36. Even pred-
nisolone is able to reduce the permeability in
children and adolescents with active Crohn’s dis-
ease and ulcerative colitis37. This effect is due to
the anti-inflammatory properties of corticos-
teroid, including the ability to inhibit the expres-
sion of pro-inflammatory cytokines such as TNF-
α and NF-κB38, although high concentrations of
steroids (prednisone and budesonide) are related
to a reduced mucosal healing39.
The use of 5-aminosalicylic acid (5-ASA) is
one of the leading treatments in the treatment of
uncomplicated mild to moderate IBD. These sub-
stances, such as mesalazine, promote the rapid
recovery of mucosal integrity through TGF-me-
diated signaling, thereby reducing intestinal per-
meability40,41.
Biological drugs, including anti-TNF-α, are
the most recently used drugs in the treatment of
IBD. They act by blocking the action of TNF-α,
reducing inflammation and restoring mucosal in-
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tegrity. Some studies with 51CrEDTA, showed a
significant reduction in intestinal mucosal perme-
ability after treatment with anti-TNF-α and the
reduction is proportional to disease activity and
mucosal healing42.
Probiotics are frequently used in functional
gastrointestinal disorders and in recent years have
been tested for the treatment of IBD, SIBO and
infectious diarrhea. Many studies highlighted the
role of probiotics in the modulation and reduction
of intestinal permeability. In a double-blind,
cross-over, placebo-controlled trial, a mixture of
Lactobacillus rhamnosus and Lactobacillus
reuteri was administered for 6 weeks in 41 chil-
dren with atopic dermatitis with increased intesti-
nal permeability. After the treatment it was as-
sessed a significant reduction in intestinal perme-
ability, as documented by the test lactulose/man-
nitol43. Furthermore, Lactobacillus rhamnosus
GG is able to accelerate the maturation of the in-
testinal barrier and tp induce the expression of
claudin 3 in animal models, while Lactobacillus
casei can increase the genes expression coding for
zonulin in Caco2 cells44,45. Saccharomyces
boulardii, in combination with the standard thera-
py, improves intestinal permeability in Crohn’s
disease patients in remission, with a clear normal-
ization of the relationship lactulose/mannitol46.
The mucosal protectors, such as sucralfate
and bismuth, are normally used for a prolonged
period in the treatment of peptic ulcer disease.
These compounds protect the epithelial cells
from the acidic gastric juices and digestive en-
zymes. They seem to be effective also in reduc-
ing the inflammation in infectious diarrhea.
Among the mucosal protectors, the gelatin tan-
nate is emerging between the most promising
intestinal barrier modulator drugs. It is a combi-
nation of tannic acid (penta-m-digallolyl glu-
cose) and gelatine, and could be able to create a
protective film, forming bonds with the mucin,
thus protecting the gut from the aggressive pen-
etration of commensal bacteria (barrier protec-
tor). Tannins are widely distributed throughout
the plant kingdom. Since tannic acid is one of
the principal tannins, the term tannin is ordinar-
ily used as a synonym for tannic acid. Gelatin is
a collagen derivate, which is ingested as a pow-
der insoluble at gastric acidic pH, and which be-
comes a gelatin with the increase of pH over
5.547. Gelatin tannate is commonly employed as
an intestinal astringent and present in the mar-
ket with various name, like tanagel, gelenterum
or tasectan48. This complex passes through the
stomach unaltered, and once in the intestine it
may exert its action by restoring its physiologic
barrier function. Furthermore, the well-known
astringent properties of tannins allow the pre-
cipitation of pro-inflammatory mucoproteins
from the intestinal mucus and their elimination
through the feces49,50. Recent studies presented
at international conferences but not yet pub-
lished, showed that at intestinal mucosal level,
gelatin tannate acts in a non-dissociated form as
a muco-adhesive film, with a protective effect
on the intestinal barrier (gut barrier enhancer)
and an indirect anti-inflammatory effect.
Our group studied the effect of gelatin tannate
in Dextran Sodium Sulphate (DSS)-induced mod-
el of murine colitis24-26. DSS-induced colitis rep-
resents a T-cell independent, chemically-induced
model of epithelial damage and acute inflamma-
tion, primarily driven by innate immune respons-
es. It has been recently shown that DSS directly
affects gut epithelial cells of the basal crypts, dis-
turbing the integrity of the mucosal barrier51. It
exerts its action by causing a fast alteration in the
mucus permeability and a disruption of the mucus
biophysical structure. Thus, it allows bacteria to
enter and penetrate the inner mucus layer. Once
bacteria come in contact with the epithelial cells,
enter the crypts and are taken up by epithelial
cells, GALT is triggered to react against also rela-
tively harmless commensal bacteria and to cause
an inflammation reaction22. Several studies fo-
cused on the clinical improvement of acute DSS-
induced colitis by using probiotics and antibiotics
in order to modulate the commensal microflora52-
57
. On the other hand, this model is a useful way
to evaluate those factors that can modulate the
anatomical and functional health of the gut barri-
er, by acting not only on the gut microbiota, but
also on the recovering of the mucus layer. In this
model we showed that gelatin tannate is able to
significantly reduce the clinical activity of acute
colitis compared to placebo. In particular, confo-
cal microscopy showed the polymeric protective
layer that gelatin tannate forms on the ulcerated
mucosa, thus preventing the activation of the im-
mune response58. In addition to these findings
we assessed a modulation of the microflora
composition, a restoring of mucus layer and,
consequently, of gut permeability. Furthermore,
another group showed that gelatin tannate re-
duces the proinflammatory effects of
lipopolysaccharide (LPS) in human intestinal
epithelial cells59. It is able to inhibit the intercel-
lular adhesion molecule-1 (ICAM-1) expression
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in LPS-stimulated Caco-2 cells59. ICAM-1 is in-
duced on a wide variety of cells by inflammatory
stimuli such as LPS. Together with this, adding
gelatin tannate at different concentrations induces
a dose-dependent inhibition of IL-8 and TNF-α
released by LPS-stimulated Caco-2 cells59. Final-
ly, tannic acid is a polyphenolic compound, which
includes Gallic acid that has been shown to exert
potent antioxidant effects. We can speculate that
the observed evidence could depend also on this
important characteristic of gelatin tannate.
In this scenario, gelatin tannate, thanks to its
chemical structure, seems to substitute mucus
function impairment and reestablish the gut bar-
rier permeability and homeostasis, by acting as a
gut barrier enhancer and modulating gut micro-
biota (Figure 1). Taken together, our data suggest
that not only the microbiota modulation, but also
the recovering of gut mucus layer in course of
acute colitis, can decrease the clinical disease
severity in mice. The translational therapeutic
implications of these concepts are obvious and
open new horizons to novel, targeted, and more
effective options for patients with colitis and im-
paired gut permeability58.
Conclusions
The intestinal barrier is a functional unit whose
integrity is necessary for the maintenance of nor-
mal intestinal permeability. The ability of its vari-
Figure 1. The integrity of the complex network that con-
stitutes the intestinal barrier is required for the mainte-
nance of normal intestinal permeability (A). Any alter-
ation in this balance determines an impaired function of
the intestinal barrier with the passage of luminal contents
in the underlying tissues and thus into the bloodstream,
resulting in the activation of the immune response and in
the induction of inflammation (B). Gelatin tannate, a mu-
cosal barrier protector, forms a layer similar to the intesti-
nal mucus on the surface of damaged intestinal mucosa. It
seems to be able to prevent gut microflora translocation,
thus restoring the functionality and physiological perme-
ability of the intestinal barrier (C).
ous components to ensure the physiological perme-
ability in presence of pathogenic noxae from the
external environment is essential for health mainte-
nance. When the protection exerted by intestinal
barrier fails, the immune cells come in direct con-
tact with luminal antigens. This results in the im-
pairment of normal physiological barrier functions.
The alteration of this delicate balance is the basis
for the pathogenesis of many intestinal and extra-
intestinal diseases, including infectious enterocoli-
tis, inflammatory bowel disease, irritable bowel
syndrome, small intestinal bacterial overgrowth,
celiac disease, hepatic fibrosis, food intolerances
and also allergies. Many drugs or compounds used
in the treatment of gastrointestinal diseases are able
to alter the intestinal barrier permeability. The most
important are steroids, aminosalicylates, biologics
and probiotics. Recent data highlighted and intro-
duced the possibility of using gelatin tannate, a
mucosal barrier protector, for an innovative ap-
proach in the management of intestinal diseases,
allowing an original therapeutic orientation with
the aim of enhancing mucus barrier activity and
restoring gut barrier. These results suggest how the
mucus layer recovering, beside the gut microbiota
modulation, could be a useful weapon to re-estab-
lish the physiological intestinal homeostasis after
an acute and chronic injury.
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